Moreover, increased ECM stiffness can amplify cancer’s immune evasion by altering the expression of immune checkpoint (IC) molecules like PD-L1, PD-1, and CTLA-4, potentially resulting in the failure of IC blockade (ICB) therapy. This evidence concerns the gene CTLA4 and cancer.